GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (FRA:REG) » Definitions » Return-on-Tangible-Equity

RemeGen Co (FRA:REG) Return-on-Tangible-Equity : -62.26% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is RemeGen Co Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. RemeGen Co's annualized net income for the quarter that ended in Dec. 2024 was €-180.5 Mil. RemeGen Co's average shareholder tangible equity for the quarter that ended in Dec. 2024 was €289.8 Mil. Therefore, RemeGen Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2024 was -62.26%.

The historical rank and industry rank for RemeGen Co's Return-on-Tangible-Equity or its related term are showing as below:

FRA:REG' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -56.29   Med: -36.32   Max: 8.09
Current: -56.16

During the past 7 years, RemeGen Co's highest Return-on-Tangible-Equity was 8.09%. The lowest was -56.29%. And the median was -36.32%.

FRA:REG's Return-on-Tangible-Equity is ranked worse than
57.23% of 1258 companies
in the Biotechnology industry
Industry Median: -43.075 vs FRA:REG: -56.16

RemeGen Co Return-on-Tangible-Equity Historical Data

The historical data trend for RemeGen Co's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Return-on-Tangible-Equity Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Equity
Get a 7-Day Free Trial -42.23 8.36 -23.76 -35.62 -57.95

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.25 -29.78 -42.62 -52.54 -62.26

Competitive Comparison of RemeGen Co's Return-on-Tangible-Equity

For the Biotechnology subindustry, RemeGen Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RemeGen Co's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Return-on-Tangible-Equity falls into.


;
;

RemeGen Co Return-on-Tangible-Equity Calculation

RemeGen Co's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-192.603/( (422.976+241.753 )/ 2 )
=-192.603/332.3645
=-57.95 %

RemeGen Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=-180.462/( (337.909+241.753)/ 2 )
=-180.462/289.831
=-62.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


RemeGen Co  (FRA:REG) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


RemeGen Co Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.